Loading
A phase 1/2 trial of HS-10375 in non-small-cell lung cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., now recruiting.
Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) is a phase 1/2 interventional study registered as NCT05435248 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with 354 participants planned, started 2022-03-02 and due to reach its primary completion in 2025-03-31. Interventions recorded: HS-10375.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Hansoh Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.
Shares Hansoh Pharmaceutical and the tag pipeline.
Shares Hansoh Pharmaceutical, Non-small-cell lung cancer and the tag pipeline.
Shares Hansoh Pharmaceutical and the tag pipeline.
Shares Hansoh Pharmaceutical and the tag pipeline.
Shares Hansoh Pharmaceutical and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/